BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex

Blood

Volumn 103, Issue 6, 2004, Pages 2257-2265

  Hase, Hidenori ^b   Kanno, Yumiko ^b   Kojima, Masaru ^b   Hasegawa, Kaoru ^b   Sakurai, Daisuke ^b   Kojima, Hidefumi ^b   Tsuchiya, Naoyuki ^b   Tokunaga, Katsushi ^b   Masawa, Nobuhide ^b   Azuma, Miyuki ^b   Okumura, Ko ^b   Kobata, Tetsuji ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; B LYMPHOCYTE STIMULATOR; CD19 ANTIGEN; CD40 ANTIGEN; INTERLEUKIN 15; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX5; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL SURFACE; FOLLICULAR DENDRITIC CELL; GERMINAL CENTER; HUMAN; HUMAN CELL; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION;

EID: 12144286821     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2694     Document Type: Article

References (56)

1. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260-263.
2. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2:465-475.
3. Tompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108-2111.
4. Karpusas M, Cachero TG, Qian F, et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol. 2002;315:1145-1154.
5. Do RKG, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B-lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192: 953-964.
6. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697-1710.
7. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293:2111-2114.
8. Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol. 2000;1:37-41.
9. Tew JG, Wu J, Fakher M, Szakal AK, Qin D. Follicular dendritic cells: beyond the necessity of T-cell help. Trends Immunol. 2001;22:361-367.
10. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes linking natural to acquired immunity. Annu Rev Immunol. 1995;13: 127-149.
11. Poe JC, Hasegawa M, Tedder TF. CD19, CD21 and CD22: multifaceted response regulators of B lymphocyte signal transduction. Int Rev Immunol. 2001;20:739-762.
12. Matsumoto AK, Kopicky-Burd J, Carter RH, Tuveson DA. Tedder TF, Fearon DT. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med. 1991;173:55-64.
13. Botto M, Walport MJ. Hereditary deficiency of C3 in animals and humans. Int Rev Immunol. 1993; 10:37-50.
14. Pepys MB. Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med. 1974;140:126-145.
15. Bitter-Suermann D, Burger R. C3 deficiencies. Curr Top Microbiol Immunol. 1989;153:223-233.
16. Fischer MB, Ma M, Goerg S, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol. 1996; 157:549-556.
17. Wessels MR, Butko P, Ma M, Warren HB, Lage AL. Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A. 1995;92:11490-11494.
18. Guinamard R, Okigaki M, Schlessinger J, Ravetch J. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol. 2000;1:31-36.
19. Ochsenbein AF, Pinschewer DD, Odermatt B, Carroll MC, Hengartner H, Zinkemagel RM. Protective T cell-independent antiviral antibody responses are dependent on complement. J Exp Med. 1999;190:1165-1174.
20. Fischer MB, Goerg S, Shen L, et al. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science. 1998;280:582-585.
21. Thornton BP, Vetvicka V, Ross GD. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol. 1994;152:1727-1737.
22. Dempsey PW, Allison MED, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996;271:348-350.
23. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 1992;256:105-107.
24. Carter RH, Spycher MO, Ng YC, Hoffman R, Fearon DT. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol. 1988;141:457-463.
25. Tooze RM, Doody GM, Fearon DT. Counter-regualtion by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Immunity. 1997;7:59-67.
26. Chalupny NJ, Kanner SB, Schieven GL, et al. Tyrosine phosphorylation of CD19 in pre-B and mature B cells. EMBO J. 1993;12:2691-2696.
27. Krop I, Shaffer AL, Fearon DT, Schlissel MS. The signaling activity of murine CD19 is regulated during cell development. J Immunol. 1996;157:48-56.
28. Uckun FM, Burkhardt AL, Jarvis L, at al. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J Biol Chem. 1993;268:21172-21184.
29. Wang Y, Brooks SR, Li X, et al. The physiologic role of CD19 cytoplasmic tyrosines. Immunity. 2002;17:501-514.
30. Buhl AM, Cambler JC. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase. J Immunol. 1999;162:4438-4446.
31. Fujimoto M, Fujimoto Y, Poe JC, et al. CD19 regulates src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity. 2000;13:47-57.
32. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment of the B-lymphoid lineage depends on the transcription factor Pax5. Nature. 1999; 401:556-562.
33. Max EE, Wakatsuki Y, Neurath MF, Strober W. The role of BSAP in immunoglobulin isotype switching and B-cell proliferation. Curr Top Microbiol Immunol. 1995;194:449-458.
34. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159:3838-3848.
35. Azuma M, Cayabyab M, Phillips JH, Lanier LL. Requirements for CD28-dependent T cell-mediated cytotoxicity. J Immunol. 1993;150:2091-2101.
36. Karasuyama H, Kudo A, Melchers F. The proteins encoded by the VpreB and lambda 5 pre-B cell-specific genes can associate with each other and with mu heavy chain. J Exp Med. 1990;172:969-972.
37. Morimoto S, Kanno Y, Tanaka Y, et al. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol. 2000; 164:4097-4104.
38. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189: 1747-1756.
39. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002;3:822-829.
40. Kehrl JH, Riva A, Wilson GL, Thevenln C. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today. 1994;15: 432-436.
41. Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med. 2003;197:297-302.
42. Wakatsuki Y, Neurath MF, Max EE, Strober W. The B cell-specific transcription factor BSAP regulates B cell proliferation. J Exp Med. 1994; 179:1099-1108.
43. Horcher M, Souabni A, Busslinger M. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity. 2001;14:779-790.
44. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2: 945-956.
45. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity. 2003; 18:279-288.
46. Schebesta M, Pfeffer PL, Busslinger M. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity. 2002;17:473-485.
47. Ren CL, Morio T, Fu SM, Geha RS. Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med. 1994;179:673-680.
48. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000;192:1545-1552.
49. Xu J, Foy TM, Laman JD, et al. Mice deficient for the CD40 ligand. Immunity. 1994;1:423-431.
50. Renshaw BR, Fanslow WC, Armitage RJ, et al. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med. 1994;180:1889-1990.
51. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553-563.
52. Marquart HV, Svendsen A, Rasmussen JM, et al. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1995;101:60-65.
53. Takahashi K, Kozono Y, Waldschmidt TJ, et al. Mouse complement receptors type 1 (CR1; CD35) and type 2 (CR2; CD21): expression on normal B subpopulations and decreased levels during the development of autoimmunity in MRL/Ipr mice. J Immunol. 1997;159:1557-1569.
54. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity. 1997;6:107-118.
55. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000;165:6635-6643.
56. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995-999.